Japanese drugmaker Kyorin Pharmaceutical (TYO: 4569) has entered into a licensee agreement with Bayer (BAYN: DE) for the novel obstructive sleep apnea (OSA) treatment BAY2925976 and its backup compound discovered by the German pharma major.
Signup to Our Newsletter
